MYOTONIC DYSTROPHY TYPE 1 (DM1)
Clinical trials for MYOTONIC DYSTROPHY TYPE 1 (DM1) explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY TYPE 1 (DM1) trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for muscle disease: new drug enters final testing phase
Disease control OngoingThis study tests a new medicine called AOC 1001 for people with myotonic dystrophy type 1, a genetic disease that causes muscle weakness and stiffness. About 159 adults with a confirmed diagnosis will receive either the drug or a placebo by IV. The main goal is to see if the drug…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for DM1: VX-670 Long-Term safety trial opens
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). It is for people who already completed a previous study of the same drug. The main goal is to check for side effects over time.
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 12, 2026 13:42 UTC